Humacyte (HUMA) Common Equity (2020 - 2026)
Humacyte (HUMA) posted quarterly Common Equity of $11.6 million for Q1 2026, down 67.75% year-over-year from $36.0 million in Q1 2025, and up 273.88% quarter-over-quarter from $3.1 million in Q4 2025.
Humacyte (HUMA) Common Equity (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Common Equity for 7 consecutive years, with $11.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 67.75% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $11.6 million (down 67.75% YoY), while the FY2025 annual figure was $3.1 million, up 105.9% from the prior year.
- Common Equity grew to $11.6 million in Q1 2026 per HUMA's latest filing, from $3.1 million in the prior quarter.
- Across five years, Common Equity topped out at $142.3 million in Q2 2022 and bottomed at -$63.7 million in Q3 2024.
- Historically, Common Equity has averaged $35.7 million across 5 years, with a median of $26.2 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 137.46% — and 2024, when it sank 488.82%.
- Humacyte's Common Equity stood at $116.9 million in 2022, then sank by 88.42% to $13.5 million in 2023, then tumbled by 488.82% to -$52.7 million in 2024, then jumped by 105.9% to $3.1 million in 2025, then surged by 273.88% to $11.6 million in 2026.
- Business Quant data shows HUMA's Common Equity at $11.6 million in Q1 2026, $3.1 million in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 31.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.26 Mn |
| Mar 31, 2026 | 11.62 Mn |
| Dec 31, 2025 | 3.11 Mn |
| Sep 30, 2025 | -4.75 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 36.04 Mn |
| Dec 31, 2024 | -52.67 Mn |
| Sep 30, 2024 | -63.72 Mn |
| Jun 30, 2024 | -28.29 Mn |
| Mar 31, 2024 | 26.15 Mn |
| Dec 31, 2023 | 13.55 Mn |
| Sep 30, 2023 | 36.99 Mn |
| Jun 30, 2023 | 61.12 Mn |
| Mar 31, 2023 | 81.89 Mn |
| Dec 31, 2022 | 116.93 Mn |
| Sep 30, 2022 | 118.67 Mn |
| Jun 30, 2022 | 142.26 Mn |
| Mar 31, 2022 | 103.89 Mn |
| Dec 31, 2021 | 122.17 Mn |
| Sep 30, 2021 | 75.86 Mn |